Debiopharm and Aurigene sign licence agreement
This article was originally published in Scrip
Executive Summary
The Swiss company Debiopharm and India's Aurigene Discovery Technologies have signed an exclusive worldwide licence agreement to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway. The agreement excludes Japan and the rest of Asia.